Abstract:
In recent years, frequent occurrence of enrofloxacin residues in breeding snail (
Babylonia areolate) has been a problem. To reveal the pharmacokinetic characteristics of enrofloxacin and its metabolites in
B. areolate, and to design a rational dosing method and the rest period, we fed
B. areolate with 20 mg·kg
−1 of enrofloxacin mixture at water temperature of (24.5 ± 2.5) ° C, and then sampled at 0.17
th, 0.25
th, 0.5
th, 1
st, 2
nd, 4
th, 12
th, 24
th, 48
th, 72
nd, 120
th, 168
th, 240
th and 360
th hour after the dosing. Shimadzu
8050 LC-MS/MS was used to determine the drug concentration in the tissues in each period. The results show that the drug-time data applied to the non-atrial models. in Gastropod muscle, proboscis (Including esophageal glands) and liver: the
Cmax of enrofloxacin was 7.82, 10.5 and 31.47 mg·kg
−1, respectively; the
Cmax of ciprofloxacin (Metabolite) was 0.72, 0.89 and 1.21 mg kg
−1, respectively; the enrofloxacin
tmax was 1, 4 and 4 h, respectively; the ciprofloxacin
tmax was 4, 12 and 4 h, respectively; the enrofloxacin
t1/2z was 38. 22, 52.44 and 62.40 h, respectively; the ciprofloxacin
t1/2z was 66.23, 33.11 and 27.06 h, respectively; the theoretical drug rest period was 16.94, 16.79 and 17.99 d, respectively. The results indicate that for all tissues, 20 mg·kg
−1 of enrofloxacin mixture with the
Cmax /MIC over 10 is suitable for the treatment of
B. areolate disease caused by
Vibrio harveyi (MIC, 0.45 mg·L
−1). It is recommended that the drug rest period should not be less than 440.76 ℃·d and the dosing should be once every 2 d, a total of 3 times.